Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.

Cushing TD, Metz DP, Whittington DA, McGee LR.

J Med Chem. 2012 Oct 25;55(20):8559-81. doi: 10.1021/jm300847w. Epub 2012 Sep 13. Review. No abstract available.

PMID:
22924688
2.

Phosphoinositide 3-kinase gamma in T cell biology and disease therapy.

Fung-Leung WP.

Ann N Y Acad Sci. 2013 Mar;1280:40-3. doi: 10.1111/nyas.12029.

PMID:
23551102
3.

PI3K inhibition in inflammation: Toward tailored therapies for specific diseases.

Ghigo A, Damilano F, Braccini L, Hirsch E.

Bioessays. 2010 Mar;32(3):185-96. doi: 10.1002/bies.200900150. Review.

PMID:
20162662
4.

Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.

Venable JD, Ameriks MK, Blevitt JM, Thurmond RL, Fung-Leung WP.

Recent Pat Inflamm Allergy Drug Discov. 2010 Jan;4(1):1-15. Review.

PMID:
20017720
5.

Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ.

Collier PN, Martinez-Botella G, Cornebise M, Cottrell KM, Doran JD, Griffith JP, Mahajan S, Maltais F, Moody CS, Huck EP, Wang T, Aronov AM.

J Med Chem. 2015 Jan 8;58(1):517-21. doi: 10.1021/jm500362j. Epub 2014 May 2.

PMID:
24754609
6.

Inhibition of phosphoinositide 3-kinase γ attenuates inflammation, obesity, and cardiovascular risk factors.

Wymann MP, Solinas G.

Ann N Y Acad Sci. 2013 Mar;1280:44-7. doi: 10.1111/nyas.12037.

PMID:
23551103
7.

Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function.

Fung-Leung WP.

Cell Signal. 2011 Apr;23(4):603-8. doi: 10.1016/j.cellsig.2010.10.002. Epub 2010 Oct 16. Review.

PMID:
20940048
8.

Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.

Barberis L, Hirsch E.

Thromb Haemost. 2008 Feb;99(2):279-85. doi: 10.1160/TH07-10-0632. Review.

PMID:
18278175
9.

Inhibition of phosphatidylinositol-3 kinase γ reduces pruriceptive, inflammatory, and nociceptive responses induced by trypsin in mice.

Pereira PJ, Lazarotto LF, Leal PC, Lopes TG, Morrone FB, Campos MM.

Pain. 2011 Dec;152(12):2861-9. doi: 10.1016/j.pain.2011.09.016. Epub 2011 Oct 15.

PMID:
22001656
10.

SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors.

Bell K, Sunose M, Ellard K, Cansfield A, Taylor J, Miller W, Ramsden N, Bergamini G, Neubauer G.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5257-63. doi: 10.1016/j.bmcl.2012.06.049. Epub 2012 Jun 23.

PMID:
22819766
11.

Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628.

Norman P.

Expert Opin Ther Pat. 2011 Nov;21(11):1805-10. doi: 10.1517/13543776.2011.622749. Epub 2011 Sep 23.

PMID:
21939430
12.

The p101 subunit of PI3Kγ restores activation by Gβ mutants deficient in stimulating p110γ.

Shymanets A, Ahmadian MR, Kössmeier KT, Wetzker R, Harteneck C, Nürnberg B.

Biochem J. 2012 Feb 1;441(3):851-8. doi: 10.1042/BJ20111664.

PMID:
22054284
13.

Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases.

Sriskantharajah S, Hamblin N, Worsley S, Calver AR, Hessel EM, Amour A.

Ann N Y Acad Sci. 2013 Mar;1280:35-9. doi: 10.1111/nyas.12039. Review.

PMID:
23551101
14.

PI3Kγ deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome.

Berod L, Heinemann C, Heink S, Escher A, Stadelmann C, Drube S, Wetzker R, Norgauer J, Kamradt T.

Eur J Immunol. 2011 Mar;41(3):833-44. doi: 10.1002/eji.201040504. Epub 2011 Feb 1.

15.

Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation.

Parsons MJ, Jones RG, Tsao MS, Odermatt B, Ohashi PS, Woodgett JR.

J Immunol. 2001 Jul 1;167(1):42-8.

16.

Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.

Ward SG, Finan P.

Curr Opin Pharmacol. 2003 Aug;3(4):426-34. Review.

PMID:
12901953
17.

Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.

Konrad S, Ali SR, Wiege K, Syed SN, Engling L, Piekorz RP, Hirsch E, Nürnberg B, Schmidt RE, Gessner JE.

J Biol Chem. 2008 Nov 28;283(48):33296-303. doi: 10.1074/jbc.M804617200. Epub 2008 Sep 11.

18.

[Study of isoenzymes of lymphocyte populations during controlled immunization and in autoimmune pathology].

San'ko NM, Kaliia ES, Matveĭkov GP, Levin VI.

Gematol Transfuziol. 1990 Jul;35(7):10-3. Russian.

PMID:
2210315
19.

[Adenylate cyclase content of T- and B-lymphocytes of mice of different genotypes in an experimental autoimmune state].

Robinson MV, Shurlygina AV, Trufakin VA.

Tsitologiia. 1982 Jul;24(7):829-32. Russian.

PMID:
6982548
20.

Therapeutic potential of phosphoinositide 3-kinase inhibitors.

Ward S, Sotsios Y, Dowden J, Bruce I, Finan P.

Chem Biol. 2003 Mar;10(3):207-13. Review.

Supplemental Content

Support Center